Menu
X
Həkim Haqqında
  

Kardiologiya

Prof. Dr. Nevrez Koyla, İstanbul Universiteti İstanbul Tibb Fakültəsindən məzun oldu. İxtisas təhsilini isə yenə İstanbul Universiteti İstanbul Tibb Fakültəsi Daxili Xəstəlikləri Fundamental elm sahəsindən tamamladı. Evli və bir qız uşağı atası olan Prof. Dr. Koyla, sırasıyla; Iğdır Dövlət Xəstəxanasında daxili xəstəlikləri mütəxəssisi, İstanbul Universiteti İstanbul Tibb Fakültəsi Daxili Xəstəlikləri Fundamental elm sahəsindən mütəxəssis araşdırma vəzifəlisi və Kardioloji Fundamental elm sahəsindən müəllim olaraq vəzifə etdi. 2011-ci ildə Anadolu Sağlamlıq Mərkəzində işə başlayan Prof. Dr. Koyla, hələ də daxili xəstəlikləri və kardioloqa mütəxəssisi olaraq vəzifəsini davam etdirir.

Umumi Məlumatlar
  • Təhsil / Təcrübə / Təlimlər

    Universitet
    İstanbul Universiteti İstanbul Tibb Fakültəsi, İstanbul 1981
    İxtisas təhsili
    İstanbul Universiteti İstanbul Tibb Fakültəsi, Daxili Xəstəlikləri Fundamental elm sahəsi, İstanbul 1986
    Dosent
    1990
    Professor
    1996

  • Ixtisaslaşmış Olduğu Sahələr

    Yüksək təzyiq
    Ürək çatışmazlığı
    Ateroskleroz
    Koroner ürək xəstəliyi
    Lipid pozuqluqları və xroniki iskemik ürək xəstəliyi

  • Uzvlük

    American College of Cardiology (FACC)
    European Society of Cardiology (FESC)
    European Society of hypertension
    International Atherosclerosis Society
    European Atherosclerosis Society
    European Association on Cardiovascular Prevention and Rehabilitation (EACPR)
    European Heart Failure Association
    Ateroskleroz Dərnəyi (başçı və idarə heyəti üzvü)
    Farmakogenomik və fərdi Müalicə Dərnəyi (başçı köməkçisi)
    New York Academy of Sciences (aktiv deyil)
    American Society of hypertension (aktiv deyil)
     International College of Angiology (aktiv deyil)
    Türk kardiologiya Dərnəyi
    Türk Tibb Dərnəyi
    İstanbul Təbib Otağı

  • Elmi İş və Məqalələr

    1. Büyüköztürk K, Koylan N, Meriç M, Korkut F, Özsaruhan Ö, Nişancı Y, Güven Ö, Deligönül U, Erzengin F, Özkan E: The effect of oral verapamil in the treatment of essential hypertension. In: "Hypertension- The next decade: Verapamil in Focus", Eds.: A. Fleckenstein and JH Laragh, Churchill- Livingstone, p: 199- 204, 1987.
    2. Buğra Z, Meriç M, Koylan N, Adalet K, Nişancı Y, Büyüköztürk K, Ertem G: Long- term effects of coronary angioplasty on signal averaged electrocardiogram. In: “Volumetto Estratto da ICPEP 93”, Editor: A. Oto, Monduzzi Editore S.p.A, Bologna, Italy, p. 15- 18, 1993.
    3. Meriç M, Koylan N, Büyüköztürk K: Balloon Mitral Valvuloplasty. In: “Textbook of Angiology”, Ed. Chang JB, Springer- Verlag, New York, Berlin, Heidelberg, 2000. pp: 370- 380.
    4. Özben B, Bilge, AK, Koylan N: Cardiovascular aging and cardiovascular diseases in the elderly. In “Frontiers in Neurodegenerative Disorders and Aging: Fundamental aspects, Clinical Perspectives and New Insights”. Eds. T. Özben and M Chevion. IOS Press, 2004, pp: 128- 149.
    Makaleler
    1. Ekmekçi A, Güven Ö, Meriç M, Koylan N: The effect of aspirin on steady state serum digoxin concentrations in man (preliminary report). Turkish J. Res. Med. Sci., 1: 19- 20, 1983.
    2. Meriç M, Koylan N, Adalet K, Şamilgil Meriç M, Ekmekçi A, Büyüköztürk K, Ertem G, Özcan R: The clinical use of prazosin in the treatment of congestive heart failure. Med. Bull. Istanbul, 19: 19- 28, 1986.
    3. Meriç M, Nişancı Y, Adalet K, Koylan N, Korkut F, Yaşa M, Ertem G: The value of programmed electrical stimulation of the heart in the diagnosis of occult preexcitation syndrome. Med. Bull. Istanbul, 20: 17- 26, 1987.
    4. Meriç M, Adalet K, Koylan N, Karabulut N, Arseven A, Ertem G: Treatment of essential hypertension. A comparative study of labetalol and propranolol. Clin. Trials J., 25: 181- 194, 1988.
    Bu makalenin site edildiği makale:
    a) Anonymous: Bibliography Of The Current World Literature In Hypertension. J Hypertens 6 (9): H31-H34, 1988
    5. Güven Ö, Koylan N, Öztürk N, Meriç M, Ekmekçi A, Güler K: The effect of aspirin on steady state serum digoxin concentrations and digoxin clearence in patients with congestive heart failure. Turk J Med Biol Res 2: 91- 96, 1991.
    6. Seyithanoğlu BY, Atılgan D, Koylan N, Umman S, Meriç M, Ertem G: The importance of plasma fibrin destruction products within the first 24 hours of acute myocardial infarction. Med Bull Istanbul 24: 187- 196, 1991.
    7. Meriç M, Gören T, Atılgan D, Eren N, Çubukçu A, Koylan N: Metabolic, hematological, and cardiac effects of long- term Isradipine treatment in mild- to- moderate essential hypertension. J Cardiovasc Pharmacol. 1992;19 Suppl 3:S58-60.
    Bu makalenin site edildiği makaleler:
    a) Blecker D: Antihypertensive Therapy With Isradipine In Patients With Special Safety Concerns. Angiology 45 (12): 997-1008, 1994.
    b) Marcus AO: Antihypertensive Therapy With The Calcium-Channel Blocker Isradipine - An Appropriate Choice For The Diabetic Patient With Hypertension - A Review Curr Ther Res Clin E 54 (6): 763-778 Dec 1993
    8. Beşışık F, Koylan N, Umman S, Nişancı Y: Cardiac abnormalities and complications in a patient with Emery- Dreifuss muscular dystrophy. Med Bull Istanbul 26: 92- 98, 1993.
    9. Yılmaz E, Adalet K, Yılmaz G, Badur S, Erzengin F, Koylan N, Özsaruhan Ö, Ertem G, Büyüköztürk K: Importance of serum anticardiolipin antibody levels in coronary heart disease. Clin Cardiol 17: 117- 121, 1994.
    Bu makalenin site edildiği makaleler:
    a) Gurlek A, Ozdol C, Pamir G, et al. Association between anticardiolipin antibodies and recurrent cardiac events in patients with acute coronary syndrome. INTERNATIONAL HEART JOURNAL 46 (4): 631-638 JUL 2005
    b) Brey RL, Chapman J, Levine SR, et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. LUPUS 12 (7): 508-513 2003
    c) Berliner JI, Rybicki AC, Kaplan RC, et al. Elevated levels of Factor XI are associated with cardiovascular disease in women. THROMBOSIS RESEARCH 107 (1-2): 55-60 JUL 15 2002.
    d) Reshetnyak TM, Kotelnikova GP, Fomitcheva OA, et al. Cardiological aspects of the antiphospholipid syndrome. Part I. Valvular lesions in the primary and secondary antiphospholipid syndrome and systemic lupus erythematosus. KARDIOLOGIYA 42 (8): 38-43 2002
    e) Brey RL, Abbott RD, Curb JD, Et Al. Beta(2)-Glycoprotein 1-Dependent Anticardiolipin Antibodies And Risk Of Ischemic Stroke And Myocardial Infarction - The Honolulu Heart Program. Stroke 32 (8): 1701-1706, 2001.
    f) Seijas M, Vazquez CM, Rivera A, Et Al. Prevalence Of Anti-Phospholipid Syndrome Among Patients Aged Less Than 65 Years With Acute Myocardial Infarction. Rev Clin Esp 201 (3): 118-121, 2001
    g) Brighton TA, Chesterman CN: The Clinical Significance Of Antiphospholipid Antibodies In Patients Without Autoimmune Disease. Aust Nz J Med 30 (6): 693-703, 2000
    h) Petri M. Epidemiology Of The Antiphospholipid Antibody Syndrome. J Autoimmun 15: (2) 145-151 Sep 2000
    i) Guler N, Bilge M, Eryonucu B, et al. Relation between left ventricular and/or left atrial thrombus and anticardiolipin antibodies in patients with acute myocardial infarction. AMERİÇAN JOURNAL OF CARDIOLOGY 85 (11): 1391+ JUN 1 200
    j) Limaye V, Beltrame J, Cook R, Et Al. Evaluation Of Antibodies To Beta 2-Glycoprotein 1 In The Causation Of Coronary Atherosclerosis As Part Of The Antiphospholipid Syndrome. Aust Nz J Med 29: (6) 789-793 Dec 1999
    k) Zuckerman E, Toubi E, Shiran A, Et Al. Anticardiolipin Antibodies And Acute Myocardial Infarction In Non-Systemic Lupus Erythmatosus Patients: A Controlled Prospective Study. Am J Med 101: (4) 381-386 Oct 1996
    l) Triplett Da. Protean Clinical Presentation Of Antiphospholipid-Protein Antibodies (Apa). Thromb Haemostasis 74: (1) 329-337 Jul 1995.
    10. Koylan N, Öncül A, Mercanoğlu F, Orak E, Erzengin F, Büyüköztürk K: The acute effects of cilazapril on left ventricular diastolic functions. J Cardiovasc Pharmacol 24 (Suppl. 3): S42- S44, 1994.
    Bu makalenin site edildiği makale:
    a) Wachtell K, Bella JN, Rokkedal J, Et Al. Change In Diastolic Left Ventricular Filling After One Year Of Antihypertensive Treatment - The Losartan Intervention For Endpoint Reduction In Hypertension (LIFE) Study. Circulation 105 (9): 1071-1076, 2002.
    11. Özsaruhan Ö, Öncül A, Nişancı Y, Umman S, Koylan N, Emel O, Büyüköztürk K, Ertem G: Influence of global system of mobile telephones on permanent pacemakers. Reblampa 8: 157- 158, 1995.
    12. Adalet K, Nalbantgil İ, Kılıççıoğlu B, Koylan N, Buğra Z, Adalet I, Orak E, Umman F,Erzengin F, Büyüköztürk K: Multicenter double blind patient comparative trial with benazepril versus captopril in the treatment of mild to moderate hypertension. Med Bull İstanbul 28: 1- 9, 1995.
    13. Umman B, Meriç M, Umman S, Koylan N, Adalet K, Nişancı Y, Ertem G: The effects of coronary angioplasty on the global and regional left ventricular function in patients with angina pectoris after anterior myocardial infarction. Int J Angiol 6:199-202, 1997.
    14. Buğra Z, Koylan N, Vural A, Erzengin F, Umman B, Yilmaz E, Meriç M, Büyüköztürk K. Left ventricular geometric patterns and QT dispersion in untreated essential hypertension. Am J Hypertens 11(10):1164-70, 1998.
    Bu makalenin site edildiği makaleler:
    a) Tuncer M, Güneş Y, Güntekin U, et al. Association of increased QTc dispersion and right ventricular hypertrophy. MEDICAL SCIENCE MONITOR 2008, 14(2): CR102-CR105.
    b) Gür M, Yılmaz R, Demirbağ R, et al. Relationship between the elastic properties of aorta and QT dispersion in newly diagnosed arterial adult hypertensives. ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY 2007, 7(3): 275-280.
    c) Girardot D, Jover B, Moles JP, et al. Chronic nitric oxide synthase inhibition prevents new coronary capillary generation. J Cardiovasc Pharmacol 44 (3): 322-328 SEP 2004
    d) Balcı B, Yılmaz O, Yeşildağ O: The influence of ambulatory blood pressure profile on left ventricular geometry. Echocardiography-A Journal Of Cardiovascular Ultrasound And Allied Techniques 21 (1): 7-10 JAN 2004
    e) Salles GF, Cardoso CRL, Deccache W: Multivariate associates of QT interval parameters in diabetic patients with arterial hypertension: importance of left ventricular mass and geometric patterns. Journal Of Human Hypertension 17 (8): 561-567 AUG 2003.
    f) Seara FJG, Juanatey JRG, Sande JLM, et al. Long-term improvement of QT dispersion is unaffected by short-term changes in blood pressure during treatment of systemic hypertension with enalapril. Annals Of Noninvasive Electrocardiology 8 (1): 47-54 JAN 2003
    g) Oikarinen L, Nieminen MS, Viitasalo M, et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. J Hypertens 19 (10): 1883-1891, 2001
    h) Wolk R, Mazurek T, Lusawa T, et al. Left ventricular hypertrophy increases transepicardial dispersion of repolarisation in hypertensive patients: a differential effect on QTpeak and QTend dispersion. Eur J Clin Invest 31 (7): 563-569, 2001.
    i) Kajander OA, Kupari M, Laippala P, et al. Coronary artery disease modifies left ventricular remodelling due to heavy alcohol consumption. Alcohol Clin Exp Res 25 (2): 246-252, 2001.
    j) Hennersdorf MG, Strauer BE. Arterial hypertension and cardiac arrhythmias J Hypertens 19 (2): 167-177, 2001.
    k) Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 36 (6): 1749-1766, 2000.
    15. Onat A, Tokgözoğlu L, Soydan İ, Sansoy V, Koylan N, Mahley RW. Higher Efficacy of 10 mg/day of Simvastatin in Turkish Patients with Hyperlipidemia, Türk Kardiyol Dern Arş 2000; 28:635-642
    16. Onat A, Soydan I, Tokgözoğlu L, Sansoy V, Koylan N, Domaniç N, Ural D for the Riskburden Study Group: Guideline implementation in a multicenter study with an estimated 44% relative cardiovascular event risk reduction. CLINICAL CARDIOLOGY 26(5): 243- 249, 2003.

İxtisaslar
  • Kardiologiya
Videolar

image

© 2017 Turkiye Xestexanalari.

Site Yapıcı